Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 10,804 shares at $11.03 ($119K) on 2025-08-01, disclosed to the SEC on 2025-08-01.
Scheduled sale ($119k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.03 | 5,402 | $60K | 50.0% |
| 2 | $11.03 | 5,402 | $60K | 50.0% |
| Total | $11.03 avg | 10,804 | $119K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |